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Objectives: We developed a patient centred approach to chronic disease self management by providing
information designed to promote patient choice. We then conducted a randomised controlled trial of the
approach in inflammatory bowel disease (IBD) to assess whether it could alter clinical outcome and affect
health service use.
Design: A multicentre cluster randomised controlled trial.
Setting: The trial was conducted in the outpatient departments of 19 hospitals with randomisation by
treatment centre, 10 control sites, and nine intervention sites. For patients at intervention sites, an
individual self management plan was negotiated and written information provided.
Participants: A total of 700 patients with established inflammatory bowel disease were recruited.
Main outcome measures: Main outcome measures recorded at one year were: quality of life, health
service resource use, and patient satisfaction. Secondary outcomes included measures of enablement—
confidence to cope with the condition.
Results: One year following the intervention, self managing patients had made fewer hospital visits
(difference 21.04 (95% confidence interval (CI) 21.43 to 20.65); p,0.001) without increase in the
number of primary care visits, and quality of life was maintained without evidence of anxiety about the
programme. The two groups were similar with respect to satisfaction with consultations. Immediately after
the initial consultation, those who had undergone self management training reported greater confidence in
being able to cope with their condition (difference 0.90 (95% CI 0.12–1.68); p,0.03).
Conclusions: Adoption of this approach for the management of chronic disease such as IBD in the NHS
and other managed health care organisations would considerably reduce health provision costs and
benefit disease control.
C
hronic diseases are disruptive for patients and place
considerable demands on health service costs and
manpower. In the UK, most patients with such
disorders rely on hospital based services for treatment which
have traditionally tended to provide little or no patient
involvement and only limited support for disease related
problems between hospital visits. As most chronic diseases
follow an unpredictable clinical course, fixed appointment
systems rarely provide coincidence of attendance and disease
relapse, which results in both high non-attendance rates
(approximately 12% across all specialities1) and inadequate
access for those in need of urgent attention. An additional
dilemma in the management of chronic diseases is that on
the one hand, patients are increasingly demanding greater
autonomy while on the other, health professionals are
anxious about losing control of patients in their care. In
response, there has been increasing recognition that self
management constitutes an important aspect of coping with
long term illness.2 In some instances, self care approaches
have been incorporated into disease management through
schemes which involve a development of shared guidelines
designed to treat episodes of disease activity and to alleviate
symptoms.3–5 Self management plans provide patients with a
framework within which to understand their disease and a
basis for discussion of therapeutic options. Self management
is based on the premise that provision of good quality patient
information empowers patients to be more involved in their
care,6 and evidence is accumulating to show that patient
education improves disease control in chronic illness.7
Over the past six years, we have developed a self manage-
ment package designed to bridge the gap between the
clinicians requirement for continuity of clinical care and
patients’ requirements for more involvement in disease
management.8 The components of the system we have
developed are outlined in box 1. The aim of our study was
to determine whether this approach could lead to a more
appropriate use of health service resources and improve
symptoms. The study was designed to expand greatly upon
our previously published early report.4 It was on a far larger
scale (700 patients recruited), patient information was more
developed, and it was more pragmatic, being administered in
a number of randomly selected hospitals throughout a region
rather than one enthusiastic unit.
We used inflammatory bowel disease (IBD) as a suitable
example of a chronic disease to test our approach. IBD
(Crohn’s disease and ulcerative colitis) affects approximately
175 000 people in the UK9 (symptoms include bloody
diarrhoea, abdominal pain, and weight loss, and follow a
relapsing course with periods of remission). The aetiology is
unknown and medical treatment is ameliorative rather than
curative; many patients need maintenance treatment with
drugs whose dose varies according to disease severity. Although
recently developed national management guidelines9 10 state
Abbreviations: IBD, inflammatory bowel disease; IBDQ, inflammatory
bowel disease questionnaire; HADS, hospital anxiety and depression
scale; PEI, patient enablement instrument; ICC, intraclass correlation
coefficient; DNAs, did not attend for clinic appointment
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that patients with IBD should be provided with information
on treatment options, recent surveys reveal that patients still
feel insufficiently informed and want greater involvement in
their treatment.11
METHODS
The study design was a multicentre trial with randomisation
by treatment centre (cluster randomisation). This method
was chosen to avoid the risks of contamination within
centres, as staff training, an essential part of the intervention,
could only be delivered to entire clinical teams. All 24 district
hospitals in the North West of England (population
6.7 million; UK census data 2002) with gastroenterology
departments were approached and 19 agreed to participate
(of the other five sites, including one teaching hospital, three
failed to reply and two were already engaged in IBD research
and declined to participate). The 19 hospitals (seven teaching
hospitals and 12 non-teaching hospitals) were then randomly
allocated either to continue to provide treatment as usual (10
sites) or to deliver the self management programme to
eligible patients attending the outpatient clinics (nine sites).
At the time of recruitment, 15 centres had a policy of
following up all patients with IBD on a long term basis (six
randomised to intervention), two sites discharged patients
when their symptoms had been quiescent for more than one
year (both randomised to intervention), and at two sites
there was no consistent follow up policy (one randomised to
intervention).
The project was presented to and approved by the North
West region multicentre research ethics committee (MREC
98/8/23).
Patients
Eligible patients had established ulcerative colitis or Crohn’s
disease, were over the age of 16 years, were able to write
English, and were attending a follow up clinic. Patients were
recruited during a 13 month period (July 1999–August 2000)
and followed for 12 months. The trial ended 12 months after
the last patient entered the study.
The intervention
Clinicians in the intervention group of hospitals received a
two hour training session in ‘‘patient centred consultations in
gastroenterology’’. Training took place after site randomisa-
tion and before recruitment of patients and aimed to fully
engage the specialists in the trial and to provide them with
the basic skills needed to carry out the intervention. Training
encompassed the principles of patient centred medicine
advocated by Stewart and colleagues12 which were adapted
and applied to self management of IBD. An expert in
postgraduate medical education led the sessions using role
play and video feedback.13
After commencement of the study, the first 38 eligible
patients who gave informed written consent were recruited
from each of the 19 sites (mean recruitment period per site
8 months (range 3–13)). When the target number of 38
patients was reached, recruitment was stopped in that centre.
Patients at control sites continued to receive the management
process deemed appropriate by the hospital specialist. Those
at intervention sites went on to participate in a patient
centred consultation conducted by a clinician during which a
self management plan was negotiated and written into the
guidebook. Patients were instructed to telephone a specified
number if they felt an unscheduled appointment was neces-
sary, according to the circumstances listed in the guidebook.
Patients were not given access to on demand colonoscopies.
As can be seen from box 1, there were four components to
the intervention which were delivered as deemed appropriate
to the individual’s condition by the consultants at the
intervention sites. It was recognised that giving the full
intervention might not be possible for all patients; in
particular, those with active uncontrolled disease at recruit-
ment for whom an effective treatment regimen had yet to be
established might not be given a written self management
plan straight away and might still require fixed appointments
as well as being given open access for self referral.
Data collection
Demographic data and details of illness duration and severity
were collected from all patients. The inflammatory bowel
disease questionnaire (IBDQ)14 was used at the start and end
of the trial to measure disease specific quality of life. Anxiety
and depression was scored using the hospital anxiety and
depression scale (HADS).15 Patient enablement was mea-
sured after the initial consultation using the patient enable-
ment instrument (PEI).16 Satisfaction was measured using
the consultation satisfaction questionnaire17 after the initial
consultation. Patients provided an estimate of the number of
general practitioner visits on the entrance and exit question-
naires. Medical records were examined to record both IBD and
IBD related outpatient visits during the study year and preced-
ing year; drug treatments, number of investigations, and
number of hospitalisations during the study were also noted.
Healthcare resource use
Health service resource use was determined using both
patient diary data (for general practitioner and hospital
visits) and hospital records data for each patient. Details of
how costs were estimated and analysed are available from
other sources.18
Sample size and recruitment
Analysis was performed on an intention to treat basis. The
power calculation was based on the IBDQ14 which is made up
of 32 items each recorded on a seven point scale, with higher
scores representing improved quality of life. A 1 point
improvement on a quarter of items would increase the
IBDQ score by 8 points. With an estimated within treatment
arm standard deviation of 25 and an intraclass correlation
coefficient (ICC) of 0.02 (the upper 95% confidence limit of
the ICC from an unpublished study by one of the authors,
AR), a trial with eight treatment centres in each arm (16
sites) and 40 patients per treatment centre (640) would have
a power of 81% to detect such a difference at a 0.05
Box 1 Components of the intervention
(a) Provision of a patient guidebook containing a combi-
nation of lay and traditional evidence based knowledge
(guidebooks for ulcerative colitis and Crohn’s disease
were developed with patients prior to the study26). The
full colour pocket sized guidebooks27 contained infor-
mation about investigation, treatment, and self man-
agement of IBD and indicated areas where patient
choice might influence treatment decisions. A section
was included for patients to record personal details and
the negotiated self management plan was placed in the
guidebook for easy reference.
(b) Guided self management—a written self management
plan to which patients can refer when making decisions
about treatment and the need for service contact.4
(c) A patient centred approach to care provided by trained
clinicians.
(d) Direct access to services, enabling patients to self refer
based on their own evaluation of need.28
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significance level. In the event, 19 sites signed up to the study
and therefore it was decided to aim for 38 patients per site
(722 in total), which gives 80% power even after allowing for
20% withdrawals or missing data.
Outcomes derive from each patient’s hospital medical
record, the entrance questionnaire (completed following
recruitment), and the exit questionnaire. Sample sizes for
these outcomes vary depending on the data source and as a
consequence of missing values.
Statistical methods
The results of the multivariate analyses of the outcomes are
summarised in table 2. For each outcome, a set of covariates
to be controlled for was chosen on theoretical grounds prior
to any analysis. The covariates used in each analysis are listed
in table 2.
Three outcome measures were constructed from medical
records: number of appointments kept during the trial year;
number of made appointments not attended; and percentage
of patients who failed to attend at least once. The records also
allowed comparative figures to be derived for the pre-trial
year. When computing these outcome measures, the recruit-
ment appointment was excluded, as it would be inappropri-
ate to class this as either a pre-trial or in-trial appointment.
The pre-trial period is therefore taken as the 364 days prior to
the recruitment date and the in-trial period as the 364 days
following recruitment.
The main analyses were conducted using the Survey
procedures in STATA version 7.19 These procedures are based
on theoretical assumptions specific to clustered survey data.20
Hospital was designated as the cluster variable and robust
estimates of variance adopted. Continuous and count
variables were analysed by linear regression and binary
variables by logistic regression. One variable, general practi-
tioner visits, was in ordered categories of unequal range (no
visits, 1, 2, 3–5, 6–10, 11 visits or more) and was analysed by
ordered logistic regression. To adjust for missing exit
questionnaires, logistic regression was used to estimate the
probability of questionnaire return on the basis of hospital
and patient characteristics. The inverse of these probabilities
was then assigned to individual cases as weights in the
main analysis. Where data were skewed, bootstrapping
(using 10 000 repetitions and percentile confidence intervals
(CI)) was used to confirm the statistical significance of the
result.
Qualitative interviews were undertaken to obtain an
indepth understanding of both patients’ and consultants’
experience of the intervention and to focus on the processes
underlying the outcomes of the trial. All consultants at the
intervention sites were interviewed and 28 patients were
purposefully selected on the basis of responses in the exit
questionnaires to represent success (n=17) or failure
(n=11) of the intervention.
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Figure 1 Trial profile.
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RESULTS
Figure 1 shows the recruitment profile. A total of 908 patients
(519 control v 389 intervention) met the eligibility criteria for
the study; 700 (403 (78%) v 297 (76%)) consented to enter
the study, of whom 635 (365 (70% of those eligible) v 270
(69%)) provided baseline questionnaire data. These values
show that recruitment and baseline questionnaire return
rates were very similar for both groups, and were reasonably
high. The mean number of eligible patients per site was larger
for control than for test sites (51.9 v 43.2) but not
significantly so (Mann-Whitney U test comparing eligibility
numbers at intervention v test sites; p=0.19). Table 1 shows
the patient characteristics which were very similar for both
groups: 63% had ulcerative colitis, reflecting the national
prevalence pattern,9 and 25% had active disease at entry to
the study, defined pragmatically by the patient. Medical
records showed that 31% were on systemic glucocorticoster-
oids and 17% were on immunosuppressants at baseline.
It was noted that some consultants withdrew patients from
the trial before their consent was obtained. At one year,
completed exit questionnaires were available for 551 patients.
Outcome measures
Hospital appointments
The number of kept appointments reduced by approximately
one third in the intervention group compared with the
control group (difference 21.04 (95% CI 21.43 to 20.65);
p,0.001) (table 2), from 3.0 to 1.9 for the intervention group
and from 3.1 to 3.0 for the control group.
The mean number of clinic non-attendances per person
during the trial was also lower for the intervention group
(difference 20.08 (95% CI 20.15 to 20.01); p=0.034), even
after adjustment for number of non-attendances in the pre-
trial year. For both groups, non-attendance increased slightly
(from a mean of 0.07 to 0.09 for the intervention group and
from 0.13 to 0.22 for the controls).
Questionnaire data
Table 2 shows that neither IBDQ scores (difference 1.94 (95%
CI 23.27 to 7.15); p=0.45) nor HADS scores (difference
20.35 (95% CI 21.21 to 0.51); p=0.40) differed appreciably
between the two groups at the end of the trial (even after
adjustment for baseline score). Immediately after the initial
consultation, the two groups were not significantly different
with respect to satisfaction with the consultation but after
the patient centred session, the intervention group reported a
higher enablement score (difference 0.90 (95% CI 0.12–1.68);
p=0.026).
The number of self reported disease relapses during the
year differed between groups (difference 20.36 (95% CI
20.63 to 20.09); p=0.013), with the intervention group
reporting on average 16% fewer relapses.
More patients at intervention centres self referred for at
least one appointment (43% compared with 22% in control
centres) (p,0.001). No difference was found (p=0.47)
between the groups with regard to general practitioner
appointments during the trial, after controlling for frequency
prior to the trial, along with other factors: 78% of the control
group reported fewer than three general practitioner visits for
IBD compared with 82% of the intervention group.
Data obtained from the medical records showed no
difference between the two groups in the percentage of
patients receiving corticosteroid treatment (48.6% in the
control group and 52.5% in the intervention group).
After completion of the trial, 74% of patients in the
intervention arm stated a preference to continue self
management.
Intervention subgroup analysis
Secondary analysis was undertaken for the group of
intervention patients only, to examine relationships between
those outcomes that had been found to be significantly
(p,0.05) affected by the intervention and a number of
Table 1 Demographic characteristics of the 635 patients at baseline
Characteristic Control Intervention
Age (y)
Mean (SD) 46.3 (15.1) 44.4 (14.9)
Range 17–86 18–81
Sex (n (%))
Male 157 (43) 112 (41.5)
Female 208 (57) 158 (58.5)
Work status (n (%))
In work 211 (57.8) 144 (57.1)
Retired 81 (22.2) 53 (19.6)
Long term sickness 9 (2.5) 15 (5.6)
Other 64 (17.6) 48 (17.7)
Marital status (n (%))
Married/cohabiting 222 (60.8) 172 (63.7)
Education (n (%))
Continued after 16 y 165 (45.2) 112 (41.5)
Degree or professional qualification 99 (27.1) 67 (24.8)
Disease type (n (%))
Ulcerative colitis 226 (61.9) 177 (65.6)
Crohn’s disease 139 (38.1) 92 (34.1)
Missing — 1 (0.4)
Activity at baseline (n (%))
Active 85 (23.3) 69 (29.6)
Relapse in past 18 months 196 (53.7) 137 (50.7)
In remission—no flare ups in past 18 months 58 (15.9) 47 (17.4)
Missing 26 (7.1) 17 (6.3)
Duration of illness (n (%))
0–2 y 86 (23.6) 68 (25.3)
3–9 y 141 (38.7) 116 (43.8)
10 y or longer 137 (37.7) 81 (30.5)
Baseline health status measures (n (%))
Disease specific quality of life value (mean (SD)) 165.4 (37.4)* 168.1 (36.2)
Anxiety and depression score (mean (SD)) 12.2 (7.5)` 11.6 (7.1)1
*n = 358; n = 262; `n = 364; 1n= 265.
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patient characteristics: IBDQ scores at baseline; disease
duration; diagnosis (ulcerative colitis or Crohn’s disease);
sex; age; and level of education (left education at 16 years;
stayed beyond 16 years; gained degree or professional
qualification). Two further variables were included as
indicators of the extent patients reported (at the end of the
trial) their consultant had engaged them in the intervention:
whether or not the patient said they were given open access
to appointments; and whether or not they said they were
provided with a self management plan (the percentage of
patients per centre saying they had a plan ranged from 14%
to 61% (mean 43%)). For each outcome, a backwards
stepwise linear (or logistic regression) regression was run
using this set of predictors while controlling for the values of
the outcome at baseline.
This analysis found that the number of appointments kept
by intervention patients during the trial was unaffected by
any of the patient characteristics (p.0.05 in all cases) but
was reduced by an average of 0.44 consultations for patients
who reported being given open access compared with those
who did not (p=0.033). The extent to which patients made
appointments for themselves was also—not surprisingly—
related to being given open access (p=0.023). Younger
patients more frequently made appointments for themselves
(p=0.002), even though younger patients were no more
likely to be given open access (logistic regression; p=0.08).
The only factor found to be related to ‘‘did not attend for
clinic appointment (DNAs)’’ was IBDQ score, such that
patients with higher quality of life scores at baseline were
slightly less likely to DNA (p=0.036). The frequency of
relapses was also lower for patients with higher initial quality
of life scores (p=0.010). Feelings of enablement after the
initial consultation demonstrated a wider range of associa-
tions, with reported enablement being higher for women
(p=0.005), for older people (p=0.006), for more recently
diagnosed patients (p=0.045), and for those with higher
initial IBDQ scores (p=0.026).
Hospital centre effect before trial
To examine the extent to which hospitals varied initially in
terms of patient outcome measures, ICCs were computed to
indicate how strongly patient outcomes were clustered
within centres during the year prior to the trial. The results
revealed low ICCs with respect to IBDQ (0.033) and HADS
(0.030) scores, DNAs (0.047), and relapses (0.054). There was
some variation between centres with respect to numbers of
hospital appointments, where the ICC was 0.109.
Qualitative analysis
The indepth interviews gave an insight into the different
components of our approach and helped to indicate which
parts of the intervention were of most use. In particular, we
found that the guidebooks were well received by both
patients and clinicians while the intervention itself was
stated to have clarified responsibilities and to have provided
confidence in symptom management. The analysis does
suggest that the approach may not be suitable for those with
multiple social problems.
DISCUSSION
IBD is a condition well suited for guided patient self
management; it is chronic with unpredictable relapses,
therapy is required quickly when relapse occurs, and routine
follow up visits rarely coincide with relapse. We have now
shown that the great majority of IBD patients are both
willing and able to self manage their condition, achieve
benefit from so doing, and can reduce their use of health
services.
We hypothesised that the initial patient centred consulta-
tion would improve patients’ ability to self manage and used
the PEI as an indicator of enablement. The PEI has not
previously been used in a specialist care setting but enable-
ment has been proposed as an alternative outcome to
satisfaction.21 Our findings indicate that the initial patient
centred consultation left patients feeling more enabled.
Table 2 Summary of results
Control group Intervention group
Coefficient (SEM)
method* 95% CI p Valuen Mean (SD) n Mean (SD)
Outcomes from hospital records
No of kept appointments during trial` 364 3.0 (2.5) 274 1.9 (2.2) 21.04 (0.19) R 21.43 to 20.65 ,0.001
No of DNAs during trial1 364 0.22 (0.78) 274 0.09 (0.34) 20.08 (0.03) R 20.15 to 20.01 0.034
Percentage of patients who DNA 364 12.1% 274 8.0% 0.66 (0.25) L 0.30 to 1.47 0.29
Outcomes from entrance questionnaire
Enablement (after initial consultation)** 352 3.0 (3.9) 260 4.0 (3.9) 0.90 (0.37) R 0.12 to 1.68 0.026
Satisfaction with initial consultation** 358 62.1 (12.3) 260 65.4 (12.0) 3.47 (1.95) R 20.62 to 7.56 0.09
Outcomes from exit questionnaire
IBDQ 296 167.7 (37.5) 236 172.3 (36.6) 1.94 (2.48) R 23.27 to 7.15 0.45
HADS`` 306 12.3 (7.6) 242 11.7 (7.9) 20.35 (0.41) R 21.21 to 0.51 0.40
No of reported relapses during trial year11 246 2.2 (2.5) 206 1.8 (2.2) 20.36 (0.13) R 20.63 to 20.09 0.013
Frequency of GP visits during trial year (%
making no more than 2 visits)
288 78.5% 232 81.9% 1.17 (0.24) O 0.75 to 1.81 0.47
% patients making appointment for themselves
(excluding those with no appointments)***
250 22.0% 144 43.1% 2.70 (0.65) L 1.63 to 4.46 0.001
DNA, did not attend for clinic appointment; IBDQ, inflammatory bowel disease questionnaire; HADS, hospital anxiety and depression scale; 95% CI, 95%
confidence interval.
*Coefficients and standard errors are adjusted for covariates. For linear regressions (R), the coefficient is the adjusted mean difference between control and
intervention groups; for logistic and ordered logistic regressions (L and O), the adjusted odds ratio.
Frequency of general practitioner (GP) visits is presented here for convenience as a percentage but the underlying data entered into the multivariable analysis
were on an ordinal scale (no visits, 1, 2, 3–5, 6–10, 11 visits or more).
`Adjusted for appointments kept in pre-trial year, entrance IBDQ, sex, age, and duration of illness.
1Adjusted for DNAs in the pre-trial year, appointments kept in the previous year, entrance IBDQ, sex, age, and duration of illness.
Adjusted for percentage who DNA in the pre-trial year, appointments kept in the previous year, entrance IBDQ, sex, age, and duration of illness.
**Adjusted for entrance IBDQ, sex, age, duration of illness, and diagnosis.
Adjusted for entrance IBDQ, sex, age, duration of illness, and diagnosis
``Adjusted for entrance HADS, sex, age, duration of illness, and diagnosis.
11Adjusted for relapses in pre-trial year, entrance IBDQ, sex, age, duration of illness, and diagnosis.
Adjusted for GP visits in the pre-trial year, entrance IBDQ, sex, age, and duration of illness.
***Adjusted for entrance IBDQ, sex, age, duration of illness, diagnosis, and education.
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Because enablement was only measured at the initial
consultation, we cannot say anything about longer term
effects on enablement but the information obtained at the
qualitative interviews indicated that while in general all
patients enjoyed a good doctor-patient relationship, negotia-
tion of a self management plan further clarified treatment
options and enhanced confidence in recognising and treating
disease relapse for the entire one year trial period. Using data
on relapses obtained from patient diaries (kept by all patients
in the trial18), we suspect that the reduction in reported
relapses by the intervention group is due to patients changing
their definition of a relapse following discussion with
consultants.
Findings from the subgroup analysis of intervention
patients included: lack of a significant influence of education
level on any outcome; that those reporting being given open
access had fewer total appointments and made more
appointments for themselves; and outcomes were no
different for patients who reported a self management plan
compared with those who did not. A caveat to the finding on
the lack of effect of self management plans is that the
variable may reflect patients’ understanding and memory of
what information they were given as much as the actual
possession of written plans.
Limitations of the trial
There were minor pre-trial differences in discharge policies
between the centres; in particular, the two sites where there
was a policy to discharge patients with quiescent disease
were both randomised to the intervention group. This
however would have biased the trial outcome in favour of
‘‘no effect’’ because if patients in remission are discharged,
there will be more patients with active disease at the clinics,
and it was expected that those with quiescent disease would
be most likely to benefit from the intervention. It is of
interest to note, however, that despite these discharge policy
differences, we found no centre differences in patient
characteristics at the beginning of the trial.
Our study found that uptake of self management was
dependent on the hospital centre delivering the intervention.
As this was a pragmatic trial of a complex intervention
delivered through a diverse group of hospital specialists in
different centres, it is perhaps not surprising that not all
eligible patients received the full intervention. The most likely
explanation for this variation in compliance between centres
is variation in degree of engagement by consultants in the
principles of patient centred self management. In post study
interviews we conducted, some consultants expressed strong
ideas about who was suitable for the intervention and were
reluctant to give patients more control. However, while we
recognise that there are a small number for whom this
approach is unsuitable, it seems equally true that most
patients have a right to decide how much they want to take
responsibility for self management at different times during
their illness.
The initial time burden of patient education was also
reported by some clinicians to be the limiting factor in
whether or not the intervention was delivered in clinic.
Overall however, our study has demonstrated that the greater
time taken to introduce patients to self management is more
than offset by a reduction in the number of outpatient follow
up visits, a benefit which would be expected to steadily
increase with time.
Strengths of the trial
A key factor in the success of self management is known to
be provision of relevant written information.22 However, in
IBD, most available information has been shown to be of
limited utility in supporting shared decision making, being
predominantly biomedically, rather than patient, focused.23
Indeed, a recent study found that some IBD related
information actually worsened quality of life,24 the informa-
tion was irrelevant to patients’ needs and impossible to
understand without reinforcement by health professionals.
Our information, in contrast, which was designed in close
collaboration with patients and contained lay experiences of
living with chronic disease, has been found to be both
relevant and supportive.25
Patients also reported that self referral to clinics improved
their ability to self manage and the post-study interviews
with clinicians revealed evidence that patient self referrals
were appropriate. Some however were concerned that
patients might avoid contacting the hospital and thereby
put themselves at risk. While we found no evidence for this,
such concern could be addressed by greater clarification of
criteria for self referral by clinicians.
A further important finding was that self management
reduced patient cost, a benefit primarily driven by reduction
in both outpatient and inpatient hospital contacts. Although
the absolute cost reduction per patient per year was relatively
small (£148),18 given the prevalence of IBD (200 per 100 000),
savings for an entire healthcare system would be enormous,
probably in the region of £20 million a year in the UK. If
more chronic diseases were managed in the same way,
savings would be considerably greater.
In conclusion, adoption of guided self management was
generally popular both with patients and clinicians, reduced
use of hospital services without burden to primary care, and
increased quality of care without an adverse effect on disease
control at the same time as reducing cost. More widespread
adoption of this programme for patients with IBD and other
chronic medical disorders, particularly those with relapsing
remitting patterns, now seems indicated.
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